In this context, the aim of this review is to highlight the active role of GLP-1 agonists and the main outcomes demonstrated by clinical trials in diabetes and non-diabetic obesity aiming to reduce morbidity and mortality associated with these metabolic disorders and to improve the quality of life. The gene discussed is GLP1R; the disease is metabolic disease.